Jonathan Strickler, MD, Duke Cancer Institute, Durham, NC, discusses the potential of tucatinib for patients with HER2+ metastatic colorectal cancer and talks about the currently-recruiting MOUNTAINEER-03 trial (NCT05253651) which will investigate the use of tucatinib plus trastuzumab plus FOLFOX in the first-line setting. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.